Shield Therapeutics (STX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 6.65p
   
  • Change Today:
      0.000p
  • 52 Week High: 12.20
  • 52 Week Low: 2.35
  • Currency: UK Pounds
  • Shares Issued: 1,068.42m
  • Volume: 1,259,601
  • Market Cap: £71.05m
  • Beta: 0.03

Latest ShareCast News

Shield Therapeutics reports positive Q1 earnings

By Josh White

Date: Friday 01 May 2026

(Sharecast News) - Shield Therapeutics reported first-quarter net revenue of $18m and positive EBIT on Friday, helped by a China milestone payment and continued growth in US sales of its iron deficiency treatment ACCRUFeR.

Shield's Accrufer MA application accepted in China

By Josh White

Date: Tuesday 03 Mar 2026

(Sharecast News) - Shield Therapeutics said the Chinese National Medical Products Administration has accepted a marketing authorisation application for Accrufer, or ferric maltol, for the treatment of iron deficiency in adults.

Total Voting Rights

By Sharecast

Date: Friday 02 Jan 2026

FDA approves label extension for Shield's Accrufer 22-Dec-2025 ShareCast
FDA approves extension for ACCRUFeR® 22-Dec-2025 ShareCast
Shield Therapeutics reports strongest quarterly ... 23-Oct-2025 ShareCast
Shield Therapeutics gets FDA priority review to ... 04-Sep-2025 ShareCast
Shield Therapeutics reports sharp rise in first-... 03-Sep-2025 ShareCast
Shield Therapeutics inks exclusive licence agree... 22-Apr-2025 ShareCast
Shield Therapeutics appoints Anders Lundstrom as... 27-Jan-2025 ShareCast
Shield Therapeutics secures $10m investment, ann... 06-Dec-2024 ShareCast
Shield Therapeutics reports strong quarter for A... 29-Oct-2024 ShareCast
Shield Therapeutics announces promising paediatr... 25-Sep-2024 ShareCast
Shield Therapeutics iron deficiency treatment ap... 27-Aug-2024 ShareCast
Shield Therapeutics net sales grow in Q2, CEO st... 24-Jul-2024 ShareCast
Shield Therapeutics reports strong US progress 07-Dec-2023 ShareCast
Shield's Canadian partner files new drug submiss... 21-Mar-2022 ShareCast
Shield Therapeutics revenue falls in line with e... 17-Feb-2022 ShareCast
Shield Therapeutics enters Accrufer licensing de... 05-Jan-2022 ShareCast
Shield shares surge on expansion of US coverage ... 16-Dec-2021 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

STX Market Data

Currency UK Pounds
Share Price 6.65p
Change Today 0.000p
% Change 0.00 %
52 Week High 12.20
52 Week Low 2.35
Volume 1,259,601
Shares Issued 1,068.42m
Market Cap £71.05m
Beta 0.03

STX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
12.49% below the market average12.49% below the market average12.49% below the market average12.49% below the market average12.49% below the market average
70.73% above the sector average70.73% above the sector average70.73% above the sector average70.73% above the sector average70.73% above the sector average
Price Trend
58.74% above the market average58.74% above the market average58.74% above the market average58.74% above the market average58.74% above the market average
77.27% above the sector average77.27% above the sector average77.27% above the sector average77.27% above the sector average77.27% above the sector average
Income Not Available
Growth
64.03% above the market average64.03% above the market average64.03% above the market average64.03% above the market average64.03% above the market average
79.31% above the sector average79.31% above the sector average79.31% above the sector average79.31% above the sector average79.31% above the sector average

What The Brokers Say

Strong Buy 1
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

STX Dividends

No dividends found

Trades for 19-May-2026

Time Volume / Share Price
16:09 120,429 @ 6.65p
16:08 50 @ 6.70p
16:06 30,135 @ 6.68p
15:58 3,671 @ 6.65p
15:22 88,001 @ 6.64p

STX Key Personnel

CEO Anders Lundstrom

Top of Page